Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 1051 results for infections

  1. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  2. Cabotegravir with rilpivirine for treating HIV-1 (TA757)

    Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

  3. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for treating follicular lymphoma in adults.

  4. Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction (IPG457)

    Evidence-based recommendations on insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction. This involves making the titanium implants specially to fit the person using a model of their face.

  5. Haematological cancers: improving outcomes (NG47)

    This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.

  6. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for stress urinary incontinence – Options for women referred to specialist centres

    or extrusion. It can cause pain, vaginal discharge or bleeding, vaginal infections, or pain or problems having sex. : The mesh can also...

  7. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for pelvic organ prolapse – Options for women referred to specialist centres

    or extrusion. It can cause pain, vaginal discharge or bleeding, vaginal infections, or pain or problems having sex. : The mesh can also...

  8. Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis (IPG110)

    Evidence-based recommendations on artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis. This involves removing the diseased joints and replacing them with artificial ones.

  9. Artificial anal sphincter implantation (IPG66)

    Evidence-based recommendations on artificial anal sphincter implantation. This involves placing a circular cuff under the skin around the anus.

  10. Partial replacement of the meniscus of the knee using a biodegradable scaffold (IPG430)

    Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.

  11. Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

    Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.

  12. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.

  13. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

  14. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

  15. Quality standards advisory committee members

    Census Data Collection and Transformation Programme and Director of Covid Infection Survey About Ruth Ruth joined ONS in June 2020...